Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Fitwel & EVORA Global Launch ‘Social Performance’ Following Successful Completion of Pilot Program with Leading Companies in Real Estate




Newly branded entity-wide certification pathway quantifying health & value for “S” in ESG expands to exclusive group of early adopters for Phase 2 of launch

CANNES, France, March 11, 2024 /PRNewswire/ — Fitwel®, the global healthy building certification and data insights platform, launched phase two of its groundbreaking new solution that, for the first time, quantifies Social performance by overlaying health research and financial data to identify strategies that have the greatest impact on stakeholders and asset value. Phase one was successfully piloted last year in collaboration with sustainability advisor, EVORA Global, enlisting an exclusive first cohort of some of the largest commercial real estate owners and asset managers worldwide. This portfolio-scale certification pathway has proven to be essential for substantiating “S” data for real estate, addressing the growing demand – driven by both investors and forthcoming regulations – for a rigorous and standardized approach to integrate “Social” metrics, including health and wellbeing measures, into ESG reporting. Social Performance by Fitwel will receive recognition by GRESB for 2024 reporting.

First introduced in 2023 under the name Certified Metrics, Social Performance by Fitwel realizes the potential for an entity-wide ESG solution by offering a complimentary pathway to Fitwel’s asset certification, effectively addressing a prominent market gap. Together, the existing asset-level certification and Social Performance provide 100% portfolio assessment, allowing asset managers and investors to:

  • Generate portfolio-wide insights for social and material risk;
  • Optimize asset performance by generating gap analysis based on S criteria;
  • Report on goal-based performance with third-party certified data;
  • Compare performance to industry peers;
  • Include all assets in certification assessments.

Fitwel has begun rolling out Phase 2 of Social Performance. For more information and to become an early adopter, visit

The initial pilot of Social Performance was led by Fitwel Leadership Advisory Board (LAB) members, including BGO, Harrison Street, Hudson Pacific Properties, Lendlease Americas, PGIM, QuadReal Property Group, and Vornado Realty Trust, and expanded to a larger pilot cohort, including Barings, Kayne Anderson Real Estate, Fabrix, and others.

While voluntary ESG reporting has become the norm, nearly half of investors find the ‘S’ to be the most difficult ESG factor to codify, analyze and embed into investment strategies, according to a 2022 Deloitte Survey. At the same time, in the European market, anticipated reporting regulations will require more stringent reporting standards for ESG metrics, particularly as commercial real estate companies in Europe prepare for their first round of Corporate Sustainability Reporting Directive reporting.

The new social solution is the result of years-long analysis by Fitwel’s non-profit research arm, the Center for Active Design, on the economic impacts of the evidence-based strategies included in the Fitwel Standard. This resulted in the identification of a subset of strategies with the greatest impact on not only occupant and community health, but also material risk and financial value.

“Social Performance by Fitwel is the only certification pathway applicable to all real estate assets and designed to measure and track the Social performance of real estate funds on an entity scale. Together with EVORA Global and the first cohort of pilot users, we have made it possible to clearly define the value of Social strategies, providing structured insights to inform continuous improvement for stakeholders – an industry first,” said Joanna Frank, President & CEO of Fitwel. “Social reporting will become as commonplace as environmental reporting in the coming years, and we’re thrilled to accelerate this transformation right here at MIPIM, the largest global stage for commercial real estate in the world.”

Philippa Gill, Executive Director at EVORA Global, added: “We are delighted to be working with Fitwel on such a critical step forward for the real estate sector. Every building has been created for people, whether to live, eat, work or shop, and the new Social Performance portfolio methodology now allows investors and managers to understand and track the human and financial impact of social measures.”

Social Performance by Fitwel in Action
Pilot users from a diverse range of real estate investors and fund managers provided invaluable input which enabled the product to be ready for a full public launch.

QuadReal Property Group, a long-time strategic partner and Fitwel investor, was a first adopter of Fitwel’s social solution, Social Performance, as a pilot user, providing invaluable input to help craft a market-ready tool for the industry.

“Through thoughtful placemaking, QuadReal contributes to the resilience of local economies by creating spaces that improve health and wellbeing. Buildings are a vital component of a healthy society and we are committed to improving environments that support individual and community wellbeing. The Social Performance report by Fitwel is one way we can dive deeper into understanding the health aspects of our portfolio and how it compares to peers,” said Jamie Gray-Donald, Senior Vice President, Sustainability & EHS at QuadReal. “We have been an early user of the Fitwel certification program to support our approach to health and wellness and Social Performance provides the benchmarking summary. It allows us to continue refining specific health-promoting initiatives across the portfolio in a thoughtful and strategic way.”

Fitwel & EVORA at MIPIM
Joanna Frank and Philippa Gill will both be attending and participating at MIPIM 2024 at Palais des Festivals convention centre in Cannes, France. Joanna will be speaking on a panel session titled, Demonstrating Social Impact: Leveraging Qualitative Research for Effective Communication and Reporting on Thursday March 14th at 11:10am at the Make It Happen Stage (Palais 3).

About Fitwel
Fitwel is the world’s leading certification system committed to building health for all. Generated by expert analysis of 7,000+ academic research studies, Fitwel is implementing a vision for a healthier future where all buildings and communities are enhanced to strengthen health and well-being. Fitwel was originally created by the U.S. Centers for Disease Control (CDC) and Prevention and U.S. General Services Administration. The CDC remains the research and evaluation partner for Fitwel. The Center for Active Design (CfAD), a global not-for-profit organization, maintains the Fitwel standard and conducts objective third-party assessments that lead to certified projects. CfAD’s new business unit, Adai (pronounced “a-DAY”), is charged with expanding Fitwel to the global market, administering the program while providing best-in-class customer service and technical support. To learn more about Fitwel, please visit:

About EVORA Global
EVORA Global is a premier sustainability advisor, providing comprehensive, industry-leading climate solutions for real asset investors. With over a decade of experience, EVORA is dedicated to addressing the climate challenge posed by the real asset industry, focusing on the needs of investors in the built environment. Its clients include many of the biggest names in global real estate, including Invesco Real Estate, Hines and M&G. Founded in 2011, the company now has over 200 staff and 250 clients.

View original content:–evora-global-launch-social-performance-following-successful-completion-of-pilot-program-with-leading-companies-in-real-estate-302084597.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading